Content area

|
|

Vaskulær endotelial vækstfaktor-terapi ved iskæmisk hjertesygdom

Forfatter(e)

Abbas Ali Qayyum1, 2, Francis Richard Joshi1, Lisbeth Drozd Lund2, Rebekka Harary Søndergaard2 & Jens Kastrup1, 2

1) Kardiologisk Laboratorium, Rigshospitalet, 2) Kardiologisk Stamcellecenter, Rigshospitalet

Ugeskr Læger 2020;182:V05200344

Reference: 
UgeskrLæger 2020;182:V05200344
Blad nummer: 
Vascular endothelial growth factor therapy in ischaemic heart disease

Abbas Ali Qayyum, Francis Richard Joshi, Lisbeth Drozd Lund, Rebekka Harary Søndergaard & Jens Kastrup

Ugeskr Læger 2020;182:V05200344

Atherosclerosis of coronary arteries can result in a hypoxic state where myocardial cells may become dysfunctional or die. The oxygen sensing transcription factor hypoxia inducible factor 1 responds to low oxygen levels by elevating the production of angiogenic growth factors, such as vascular endothelial growth factor (VEGF). Despite this, endogenous processes and conventional therapies are inefficient in some patients. To stimulate angiogenesis, VEGF has been injected into the myocardium. As stated in this review, this therapy has so far been proven safe and studies are conducted in several countries, including Denmark.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Torben Mahneke | 22/10
1 Kommentar
af Flemming Amter | 19/10
1 Kommentar
af Henrik Dibbern | 18/10
1 Kommentar
af Jens Langhoff-Roos | 17/10
3 kommentarer
af Tomas Christensen Kjær | 16/10
1 Kommentar
af Lars Lindberg Andersen | 15/10
1 Kommentar
af Johan Tommy Robert Wallentin | 14/10
1 Kommentar